Aroa Biosurgery and Hydrofera team up in US

Aroa Biosurgery and Hydrofera team up in US

Connecticut & Auckland May 2, 2018: New Zealand biomedical company Aroa Biosurgery and United States medical products company Hydrofera are launching Appulse in North America.

The two companies have recently bought back their wound care businesses from Hollister Inc.

Brian Ward, CEO of Aroa Biosurgery, says the company’s Endoform wound care technology and Hydrofera Blue are complementary.

“We have both been successfully represented by Hollister, but with Hollister’s decision to divest portions of its wound care business back to the technology developers, it gives us the opportunity to now grow the businesses ourselves.”

Tom Drury, CEO of Hydrofera, says: “On June 1 we will launch Appulse and most of the Hollister sales team for Endoform and Hydrofera Blue will continue to represent both products.

“This will help ensure the same level of service to patients, clinicians and distribution partners.”

Endoform is a proprietary extracellular matrix (ECM) biomaterial, which contains a collagen scaffold and important secondary molecules to support healing.

Endoform Dermal Template was launched in the US in 2013 for the treatment of acute and chronic wounds after obtaining US Food & Drug Administration (FDA) clearance. Since then Endoform has become established as a leading product for treating diabetic and venous ulcers and been used in more than 2.5 million treatments.

Hydrofera, LLC produces a unique line of antibacterial wound dressings, utilizing its proprietary PVA and polyurethane foam technology in combination with two natural organic pigments. This unique combination of two technology platforms yields a line of advanced wound dressings that improve patient outcomes and lower treatment costs.

© Scoop Media